Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656669 · ClinicalTrials.gov registry record · NA
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT00656669 is a NA study that has completed, run by Indiana University. The registered enrollment target is 23 participants.
The verdict
NCT00656669, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer. This treatment can help shrink the tumors so they can be removed to help prevent the cancer from spreading to other parts of the body. This study is being done to test the impact of adding sunitinib as a single-agent (Segment 1), followed by sunitinib plus paclitaxel (Segment 2), followed by doxorubicin and cyclophosphamide (Segment 3). We hope the addition of sunitinib will make the treatment more effective, but we don't know if this is true.
Interventions
- DRUG sunitinib alone
- DRUG sunitinib plus paclitaxel
- DRUG doxorubicin and cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656669
The ClinicalTrials.gov registry entry for NCT00656669 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which sunitinib alone is the first listed.
NCT00656669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656669 about?
NCT00656669 is a clinical study titled "Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer". The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant (given before surgery) treatment for patients that have either inoperable or operable breast cancer. This treatment can help shrink the tumors so they can be removed to help prevent the cancer from spreading t...
What is the current status of trial NCT00656669?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2008-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00656669?
The interventions under investigation include: sunitinib alone (DRUG), sunitinib plus paclitaxel (DRUG), doxorubicin and cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT00656669?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.